Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
